FilgrastimThird Party Manufacturing in India

Filgrastim is a recombinant human granulocyte colony-stimulating factor produced by genetically engineered Escherichia coli bacteria. It is a protein that is identical in amino acid sequence to the naturally occurring G-CSF produced by the human body, except for an added N-terminal methionine needed for bacterial expression. Filgrastim works by binding to specific G-CSF receptors on the surface of hematopoietic stem cells and progenitor cells in the bone marrow. This binding activates intracellular signaling pathways that stimulate these precursor cells to proliferate, differentiate, and mature into functional neutrophils. It also promotes the release of mature neutrophils from the bone marrow storage pool into the bloodstream. Beyond increasing neutrophil count, Filgrastim enhances the functional activity of mature neutrophils, improving their ability to perform phagocytosis antibody-dependent cell-mediated cytotoxicity, and bacterial killing. Unlike the endogenous human G-CSF, Filgrastim is non-glycosylated, which affects its pharmacokinetics and clearance rate. The drug acts quickly, with neutrophil counts rising within 24 hours of administration. Filgrastim is a short-acting formulation; the PEGylated long-acting version is known as pegfilgrastim.

Therapeutic Uses

Filgrastim is indicated for:

• Chemotherapy-Induced Neutropenia: Reduces the incidence, duration, and severity of febrile neutropenia in patients receiving myelosuppressive anticancer chemotherapy for non-myeloid malignancies.
• Bone Marrow Transplantation: Accelerates neutrophil recovery after myeloblative chemotherapy and autologous or allogeneic bone marrow transplantation.
• Severe Chronic Neutropenia: Long-term daily administration for congenital, cyclic, or idiopathic neutropenia to maintain adequate neutrophil counts and reduce infections.
• Peripheral Blood Progenitor Cell Mobilization: Used to mobilize hematopoietic stem cells from the bone marrow into peripheral blood for collection via leukapheresis prior to stem cell transplantation.
• Acute Radiation Syndrome: Indicated to increase survival in patients exposed to myelosuppressive doses of radiation.
• HIV/AIDS: Used to manage neutropenia in patients with HIV receiving myelosuppressive antiretroviral therapy.

Why Manufacturers Choose Filgrastim

Filgrastim is a high-volume biologic with massive global demand, particularly for supportive care in oncology. As one of the first recombinant G-CSFs approved, it has a well-established regulatory pathway and is now available in multiple biosimilar versions, making it an attractive molecule for manufacturers with biologic and sterile injectable manufacturing capabilities. Indian manufacturers with recombinant protein expression platforms, E. coli fermentation, and aseptic filling lines can produce Filgrastim for both domestic and regulated export markets. The availability of both liquid injection pre-filled syringe lines and lyophilized powder equipment gives manufacturers flexibility to meet diverse client preferences. The WHO-GMP certified facilities needed for biologic manufacturing create a strong barrier to entry, making Filgrastim third party manufacturing in India a premium service offering for PCD franchise partners and export-oriented companies.